2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, Neutropenia, Infectious Diseases, Viral, Bacterial, Fungal, Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant, Young Adult
PAPER

6225 Gestational age-stratified maternal outcomes after intravenous versus oral irontherapy in pregnancy: A real-world cohort study

Muhammad Yousaf, MD, Talia Alexander2, Amir Kamran, MD3
1 Charleston Area Medical Center, Charleston, West Virginia, United States
2 Charleston Area Medical Center, Charleston, West Virginia, United States
3 Charleston Area Medical Center, Charleston, West Virginia, United States

Background: 

Iron deficiency anemia (IDA) affects roughly 50% of pregnancies worldwide and is associated with worse maternal outcomes. Oral iron, the standard first-line therapy, has poor bioavailability and gastrointestinal side effects that limit adherence. A 2024 Cochrane review of 12 randomized trials found that intravenous (IV) iron likely reduces anemia antenatally and postpartum, but analyses of maternal clinical outcomes were underpowered, and the 2024 US Preventive Services Task Force found the evidence on routine supplementation insufficient. The gestational age at which IV iron is given and how it relates to maternal outcomes has not been examined in real-world data. 

  

Methods: 

This retrospective cohort study used TriNetX, a federated network of de-identified health records, from January 1, 2013 to December 31, 2025. Included were women aged 18 to 55 years with a gestational age code for 10-19, 20-29, or 30-39 weeks and IDA (D50) within 7 days of that code. Within each stratum, cohorts comprised patients starting iron therapy during that window: IV iron with or without prior oral iron but no prior IV iron, or oral iron only. The first qualifying documentation of iron therapy was the index date. Analyses were run separately within each stratum with 1:1 propensity score matching on age, race, ethnicity, obesity, hypertension, diabetes, chronic kidney disease, liver disease, smoking, multiple gestation, and baseline hemoglobin. Because delivery could not be defined as an indexable outcome, follow-up was anchored to iron initiation and assumed a 40-week gestation: 30, 20, and 10 weeks post-index for 10-19, 20-29, and 30-39 weeks, respectively, extended by 6 weeks for postpartum-spanning outcomes. Binary outcomes were assessed using risk ratios (RR) with 95% confidence intervals (CI); time-to-event outcomes were assessed using Kaplan-Meier methods, hazard ratios (HR) with 95% CIs, and log-rank tests. Statistical significance was set at p<0.05. 

  

Results: 

Propensity-score matching yielded 1,572 patients at 10-19 weeks, 5,132 at 20-29 weeks, and 21,560 at 30-39 weeks. Cesarean delivery was more frequent with IV iron in every stratum: 31.9% vs 23.9% (RR 1.34, 95% CI 1.19-1.50), 36.8% vs 31.3% (RR 1.18, CI 1.11-1.24), and 27.9% vs 10.9% (RR 2.56, CI 2.45-2.67). Postpartum hemorrhage showed a similar pattern: 12.2% vs 7.1% (RR 1.73, CI 1.38-2.16), 13.2% vs 8.7% (RR 1.53, CI 1.37-1.71), and 10.2% vs 4.0% (RR 2.57, CI 2.38-2.78). Transfusion did not differ at 10-19 weeks (HR 1.09, CI 0.85-1.38, p=0.51) or 20-29 weeks (HR 0.95, CI 0.82-1.11, p=0.54) but was higher with IV iron at 30-39 weeks (4.9% vs 2.6%; HR 1.81, CI 1.63-2.01; p<0.0001). The association with preterm delivery strengthened at later gestational ages (RR 1.09, CI 0.84-1.40; RR 1.13, CI 1.00-1.27; RR 1.52, CI 1.36-1.69). At 30-39 weeks, IV iron was associated with hysterectomy (0.18% vs 0.09%; RR 1.95, CI 1.14-3.35), preeclampsia/eclampsia (11.0% vs 8.9%; RR 1.23, CI 1.16-1.31) and placental abruption (1.2% vs 0.8%; RR 1.48, CI 1.22-1.79). Sepsis, fetal demise, and peripartum cardiomyopathy did not significantly differ in any stratum; mortality only had sufficient counts to analyze at 30-39 weeks and was similar (HR 1.13, CI 0.55-2.35), though limited by low event counts. Hemorrhagic shock in every stratum, and mortality and hysterectomy at earlier gestational ages, had too few events (≤10 events per group) to analyze. 

Conclusions: 

IV iron with or without prior oral iron was associated with higher rates of cesarean delivery and postpartum hemorrhage in all three gestational age strata and, when initiated at 30-39 weeks, with higher rates of transfusion, hysterectomy, preterm delivery, preeclampsia, and placental abruption; sepsis, fetal demise, peripartum cardiomyopathy, and mortality did not differ. Associations were strongest with later initiation and likely reflect confounding by indication rather than harm, as IV iron near term is usually given for severe or acute anemia close to delivery. They do not contradict randomized evidence of hematologic benefit; route of iron may mark obstetric risk not captured by matching on coded comorbidities and hemoglobin. Limitations include the absence of a delivery anchor, requiring approximated follow-up windows and possible misclassification of outcome timing, exclusion of restricted stillbirth codes from the fetal demise definition, and residual confounding by anemia severity.  

Muhammad Yousaf, MD: No relevant conflicts of interest to declare.